Verana Health launches Qdata anti-VEGF market tracker for in-depth market analysis

Digital health company Verana Health (San Francisco) has unveiled the Qdata anti-VEGF market tracker. It is their first market tracking Data as a Service (DaaS) product.

Excessive amounts of vascular endothelial growth factor (VEGF) can cause abnormal blood vessel growth in the eyes, which, when untreated, can result in vision loss in patients with retinal diseases. Consequently, anti-VEGF therapies help preserve eyesight for patients with conditions such as age-related macular degeneration and diabetic retinopathy.

Qdata anti-VEGF market tracker supports brand-level analysis

The Qdata anti-VEGF market tracker enables comprehensive brand-level analysis. It also provides direct access to real-world data, according to Sujay Jadhav, Verana Health’s CEO. The service offers accurate and timely insights into product performance and market dynamics.

Sujay Jadhav

Real-world data is drawn from the Ameri…

Read more
  • 0

Verana Health raises $150M from Johnson & Johnson Innovation, others

Digital health company Verana Health announced last week that it raised $150 million in a Series E funding round.

San Francisco-based Verana Health’s Series E round was led by Johnson & Johnson Innovation (JJDC) and Novo Growth, the growth-stage investment arm of Novo Nordisk.

Additional participants included existing investors GV (formerly Google Ventures), Casdin Capital and Brook Byers, while new investors, including the Merck Global Health Innovation Fund, THVC and Breyer Capital joined the round, according to a news release.

Verana Health said it intends to use the proceeds from the investment to advance its life sciences product and service strategy across the drug lifecycle, enhance its value proposition to healthcare providers in its real-world data network and expand its data footprint through medical society and strategic partnerships.

The company develops the VeraQ platform and its curated Qdata for use in ophthalmology, neuro…

Read more
  • 0

Verana Health raises $150M in Series E funding

Focusing on insights based on real-world data (RWD) related to drug lifecycle and medical practice, Verana Health (San Francisco) has just hauled in $150 million Series E funding.

Verana Health’s current fundraising total is $288.8 million, according to CrunchBase.

Johnson & Johnson Innovation (JJDC) and Novo Growth led the most recent funding round.

Also joining the funding round was Merck Global Health Innovation Fund, THVC and Breyer Capital.

Prior investors include GV (formerly Google Ventures), Casdin Capital and Brook Byers.

Founded in 2018, Verana Health has established exclusive partnerships with three specialty medical societies and several Big Pharma companies. It also has customers in biotech and biopharma, and also supports contract research organizations.

Its RWD network includes input from more than 20,000 healthcare providers. In addition, the network consists of data from more than 90 million de-identified p…

Read more
  • 0

Verana Health to collaborate with Janssen on ophthalmology and urology research

Verana Health (San Francisco), which has expertise in turning clinical data into real-world evidence, announced today that it has inked a research collaboration agreement with Johnson & Johnson‘s Janssen Research & Development.

The research with Janssen will have an ophthalmology and urology focus.

In the ophthalmology space, Verana Health will analyze the American Academy of Ophthalmology’s IRIS registry data to characterize baseline patient attributes, disease progression, and treatment-based outcomes for people treated for diabetic macular edema, a complication of diabetes that impacts 750,000 Americans and may lead to severe vision loss.

The urology research will focus on early-stage prostate cancer. The first phase of the pilot will involve curating and evaluating de-identified data from a small subset of patients in the American Urological Association Quality (AQUA) registry.

“Characterizing early-stage prostate cancer ha…

Read more
  • 0